Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited, formerly known as Balaxi Ventures Limited, was incorporated on September 28, 1942, in Hyderabad, Telangana, India. The company underwent a name change in October 2020 to better reflect its focus on the pharmaceutical sector. As of March 13, 2026, Balaxi Pharmaceuticals is listed on the National Stock Exchange of India under the ticker symbol BALAXI, with a market capitalization of approximately ₹1.11 billion. The company operates with an authorized share capital of ₹400 million and a paid-up capital of ₹100 million. Balaxi Pharmaceuticals employs around 600 individuals, with a revenue of ₹2.76 billion in the trailing twelve months ending December 31, 2025. The company's registered office is located at Plot No. 409, H. No. 8-2-293, Maps Towers 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana 500096, India.

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations and builders' hardware products from contract manufacturers based in India, China, and Portugal. The company operates through an international wholesale trading model, leveraging its extensive distribution network to supply products across various regions. Specific details regarding the manufacturing plant locations, capacities, and specializations are not publicly disclosed.

The leadership team at Balaxi Pharmaceuticals Limited includes:

• Ashish Maheshwari: Managing Director and Executive Chairman since 2020.

• Kunal Mahendra Bhakta: Independent Non-Executive Director since 2017.

• Minoshi Maheshwari: Non-Executive Director since 2017.

• Gandhi Gamji: Independent Non-Executive Director since 2017.

• Mangina Srinivas Rao: Independent Non-Executive Director since 2020.

• Akshita Surana: Non-Executive Independent Director since 2024.

Balaxi Pharmaceuticals Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company supplies pharmaceutical formulations and builders' hardware products through its international wholesale trading model, leveraging its distribution network to access these markets. Specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed.

Balaxi Pharmaceuticals Limited has expanded its footprint into emerging markets such as Africa, Latin America, and Southeast Asia. The company has secured 548 product registrations across multiple therapeutic segments, facilitating its entry into these regions. Additionally, Balaxi Pharmaceuticals has established a branded FMCG business, complementing its pharmaceutical operations and providing operating leverage through well-established on-ground infrastructure and channel relationships.

Balaxi Pharmaceuticals Limited's geographic strategy involves diversification into frontier markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on securing product registrations and establishing distribution networks in these areas indicates a strategic direction aimed at reducing concentration risk and tapping into high-growth markets. This approach aligns with Balaxi Pharmaceuticals' mission to expand into 20 frontier markets over the next five years. (balaxipharma.do)

Specific details regarding Balaxi Pharmaceuticals Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's international wholesale trading model suggests that it may not have direct manufacturing facilities registered with the FDA. However, Balaxi Pharmaceuticals sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal, which may hold the necessary FDA approvals for their products.

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal. The company emphasizes that its products are procured from WHO GMP certified contract manufacturers, ensuring compliance with international quality standards. Specific details regarding WHO prequalification, EU GMP certificates, and EDQM status are not publicly disclosed.

Balaxi Pharmaceuticals Limited operates in compliance with the regulations set forth by the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory bodies. The company sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal, ensuring adherence to the necessary manufacturing licenses and approvals. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Balaxi Pharmaceuticals Limited. The company's focus on sourcing products from WHO GMP certified contract manufacturers suggests a commitment to maintaining high-quality standards and regulatory compliance.

Balaxi Pharmaceuticals Limited operates in a competitive landscape, supplying pharmaceutical formulations and builders' hardware products through its international wholesale trading model. The company's focus on frontier markets, including regions in Africa, Latin America, and Southeast Asia, positions it against both local and international competitors aiming to establish a presence in these high-growth areas. Specific market share comparisons and head-to-head analyses are not publicly available.

Balaxi Pharmaceuticals Limited differentiates itself through its extensive product portfolio, comprising 548 registrations across multiple therapeutic segments. The company's international wholesale trading model, combined with its branded FMCG business, provides operating leverage and complements its pharmaceutical operations. Additionally, Balaxi Pharmaceuticals' focus on frontier markets and its mission to expand into 20 such markets over the next five years demonstrate a strategic approach to growth and market diversification. (balaxipharma.do)

Balaxi Pharmaceuticals Limited's current strategic direction involves focusing on frontier markets, with a goal to establish a presence in 20 such markets over the next five years. (balaxipharma.do) The company's emphasis on securing product registrations and building distribution networks in these regions indicates a commitment to growth and market diversification. While specific details regarding future plans in generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services are not publicly disclosed, the company's existing operations suggest a focus on expanding its footprint in emerging markets.

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal. The company emphasizes that its products are procured from WHO GMP certified contract manufacturers, ensuring compliance with international quality standards. Specific details regarding the overall track record, export volume, consistency, and reliability indicators of these suppliers are not publicly disclosed.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the product is listed in the FDA's Orange Book or that the manufacturing facility is registered with the FDA.

• WHO GMP Certification: Ensure that the manufacturing facility holds a valid WHO GMP certificate.

• EU GMP Certification: Verify that the manufacturing facility is certified under EU GMP standards.

• ISO Certification: Check for relevant ISO certifications, such as ISO 9001 for quality management systems.

To verify these certifications, importers can request copies of the certificates from the supplier, consult the official websites of the respective regulatory bodies, or contact the regulatory agencies directly.

Importers should undertake the following steps to ensure a thorough due diligence process:

• Verify Supplier Certifications: Confirm the validity of all relevant certifications, including FDA, WHO GMP, EU GMP, and ISO.

• Assess Manufacturing Facilities: Evaluate the manufacturing facilities